Get started
Author

Xueli Mo

Observed name: X. Mo
ORCID: 0009-0007-5343-0302
Observed ORCID: 0009-0007-5343-0302
OpenAlex ID: A5090541397
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
2024 · Zefei Jiang, Quchang Ouyang, et al. · Nature Medicine · 145
The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
2003 · Bingsen Zhou, Xiyong Liu, et al. · PubMed · 84
Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance
2001 · B. Zhou, X. Mo, et al. · Cytogenetic and Genome Research · 44
Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells.
2002 · Bingsen Zhou, Shu Mi, et al. · PubMed · 24
Association of miR‐1247‐5p expression with clinicopathological parameters and prognosis in breast cancer
2018 · Peng Zhang, Changsheng Fan, et al. · International Journal of Experimental Pathology · 15
PDF
Ribozyme Cleavage Leads to Decreased Expression of Fibroblast Growth Factor Receptor 3 in Human Multiple Myeloma Cells, Which Is Associated with Apoptosis and Downregulation of Vascular Endothelial Growth Factor
2005 · Shenxian Qian, George Somlo, et al. · Oligonucleotides · 13
Utility of totally implantable venous access ports in patients with breast cancer
2019 · Peng Zhang, Jun Du, et al. · The Breast Journal · 9
PDF
Clinical application of totally implantable venous access ports for patients with breast cancer
2020 · Peng Zhang, Xueli Mo, et al. · Asian Journal of Surgery · 5
PDF
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2
2025 · Jianbin Li, Yueping Liu, et al. · Translational Breast Cancer Research · 4
Chinese expert consensus on endocrine therapy for breast cancer (2026 edition)
2026 · Chinese Consensus Group on Breast Cancer Endocrine Therapy, Yang Yuan, et al. · Translational Breast Cancer Research · 2
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
2024 · Zefei Jiang, Quchang Ouyang, et al. · Future Oncology · 1
PDF
Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial
2026 · Shaohua Zhang, Jianli Zhao, et al. · Translational Breast Cancer Research
Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study
2025 · Zhenhua Fan, Yang Yuan, et al. · International Journal of Clinical Oncology
T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study.
2024 · Ruyan Zhang, Huiping Li, et al. · Journal of Clinical Oncology
PDF
Clinical analysis of maintenance hormonal treatment for patients with advanced breast cancer after response to chemotherapy
2011 · Xueli Mo, Delin Wang, et al. · 肿瘤研究与临床
Compare and evaluate two combination regimens of vinorelbine plus gemcitabine and cisplatin pins vinorelbine for treatment of patients with advanced non-small-cell lung cancer
2008 · Delin Wang, Feng Rui-xuan, et al. · 肿瘤研究与临床
Works count: 16
Citation count: 346
H-index: 7
I10-index: 6
Year
Topic
Type